Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across cancer, cardiovascular disease and inflammation

          Learn more

        • Cancer
        • Inflammation
        • Cardiovascular
        • Programs
        • Laboratories
        • Diseases
        • Expertises
        • Services and instrumentation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your will
        • Donate in Memory
  • Impact
        • Impact

          Our research develops new diagnostics, treatments and cures for some of the most deadly and debilitating diseases affecting society today

          Learn more

        • Breakthroughs
        • Community and research
  • Careers & studies
        • Careers & Studies

          Take the next step in your career with Centenary, Australia’s foremost clinically integrated medical research institute

          Learn more

        • Career opportunities
        • Life at Centenary
        • Post-Doctorate Research
        • PhD
        • Masters
        • Honours
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events

        • News
        • Events
        • Media Hub
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Our researchers
        • Contact
  • Donate
    Centenary Institute > News > New strategy to stop melanoma spread

New strategy to stop melanoma spread

Date time 28 January, 2020
News Type News type Media release
Scientists from the Centenary Institute have developed a new therapeutic strategy that could potentially help the fight against advanced-stage melanoma.

Scientists from the Centenary Institute have developed a new therapeutic strategy that could potentially help the fight against advanced-stage melanoma.

In a study just released, the scientists were able to show that they could effectively reduce the migration and invasive properties of melanoma cells. This was achieved by successfully inhibiting the interaction between two proteins involved in intracellular trafficking (the process by which molecules cross the membranes of living cells).

The research is significant as metastasis–the process by which cancer moves to new areas of the body–is the leading cause of death in melanoma patients.

Published in the highly regarded Journal of Investigative Dermatology, the researchers first found that high expression of the protein melanophilin was indicative of poor prognosis in melanoma patients.

Employing human melanoma cell line models, the researchers were then able to demonstrate a significant reduction in the spread of cancer by blocking the ability of melanophilin to bind with the protein RAB27A (one of the critical regulators of intracellular transport).

“We have known for some time that the proteins melanophilin and RAB27A bind together and that this process could be crucial to help melanoma cells spread around the body,” said lead study author and Centenary Institute PhD researcher (Immune Imaging Program), Mr Dajiang Guo.

“By disrupting the binding of these two proteins with a recently developed blocking compound (BMD-20), we were able to successfully restrict the melanoma cell movement and invasion. What our findings suggest is that the development of new drugs that can specifically target melanophilin-RAB27A interactions are a promising target for advanced melanoma treatment,” he said.

Senior study author Dr Shweta Tikoo also from the Centenary Institute (Immune Imaging Program) notes that there is an unmet need for novel therapeutic strategies which can be developed as a standalone drug or as part of a combination therapeutic regimen in the battle against advanced melanoma.

“Melanoma has one of the highest mortality rates in the western world with the disease accounting for approximately 1,500 deaths in Australia every year. It is also the most common form of cancer affecting young Australians, those individuals aged from 15 to 39 years old,” she says.

Read the full media release here.

Read the publication in the Journal of Investigative Dermatology here.

Themes

  • Cancer

    Cancer

Media enquires

For all media and interview enquiries, please contact Tony Crawshaw, Media and Communications Manager

Phone number Phone Number 0402 770 403

Email Email t.crawshaw@centenary.org.au

Media Release

Download

Recent Stories

  • New drug target identified for inflammatory lung disease

    Researchers at the Centenary Institute and the University of Technology Sydney have identified a new drug target for the treatment and prevention of chronic obstructive pulmonary disease (COPD), an inflammatory lung disease that causes airway blockage and that makes it difficult to breathe.
    News Type: Media release
    Date 04 Jul 2022
  • Inflammation presentation awarded

    Dr Joyce Chiu from the ACRF Centenary Cancer Research Centre has won an Oral Communication Award for her talk given at the 15th World Congress on Inflammation, held in Rome, June 2022.
    News Type: Research News
    Date 01 Jul 2022
  • Meet Dr Annalicia Vaughan

    A medical researcher at the Centenary UTS Centre for Inflammation, Dr Annalicia Vaughan specialises in the gut-lung axis and its role in lung and respiratory diseases.
    News Type: Profiles
    Date 28 Jun 2022
    Dr Vaughan
  • The Centenary Institute is excited to join the Sydney Biomedical Accelerator (SBA) as primary medical research partner

    The Centenary Institute welcomes the NSW Government’s commitment to fund a new biomedical complex in Camperdown. The Chair of the Centenary Institute Board, Joseph Carrozzi AM, and its Executive Director, Professor Mathew Vadas AO, are thrilled that a biomedical complex, the Sydney Biomedical Accelerator (SBA), will now be a reality.
    News Type: Media release
    Date 17 Jun 2022

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About
  • Governance
  • Corporate information

Research

  • Programs
  • Laboratories
  • Our researchers
  • News
  • Media hub

Careers & studies

  • Career opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram